Get the Stockscreener App
0.00
100.00%
-3.41
Opthea Limited Adr stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company geographically operates Australia and United States.
See More
Previous Close:
$3.41
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$524.82M
Revenue:
$117.10K
Net Income/Loss:
$-161.61M
P/E Ratio:
0.00
EPS:
-2.4059
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$6.30
Opthea Limited Adr Stock (OPT) Company Profile
Compare OPT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OPT
Opthea Limited Adr
|
0.00 | 524.82M | 117.10K | -161.61M | 0 | -2.4059 |
|
VRTX
Vertex Pharmaceuticals Inc
|
440.51 | 129.44B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.93 | 61.42B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
621.15 | 38.44B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
275.39 | 33.29B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.31 | 26.95B | 3.81B | -644.79M | -669.77M | -6.24 |
Opthea Limited Adr Stock (OPT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-25-25 | Downgrade | Jefferies | Buy → Underperform |
| Mar-25-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-08-22 | Initiated | H.C. Wainwright | Buy |
| Apr-26-22 | Initiated | SVB Leerink | Outperform |
| Nov-17-20 | Initiated | Citigroup | Buy |
| Nov-11-20 | Initiated | Oppenheimer | Outperform |
| Nov-11-20 | Initiated | SVB Leerink | Outperform |
| Nov-11-20 | Initiated | Truist | Buy |
View All
Opthea Limited Adr Stock (OPT) Latest News
Brokerages Set Opthea Limited (NASDAQ:OPT) PT at $1.33 - Defense World
Layoff Tracker: Opthea Slashes 65% of Staff, Pfizer Cuts 56 - BioSpace
Opthea Halts Wet AMD Clinical Trials By Investing.com - Investing.com South Africa
Opthea Halts Wet AMD Clinical Trials - Investing.com
Opthea Limited (NASDAQ:OPT) Receives $1.33 Consensus PT from Brokerages - Defense World
Hold Rating Issued for Opthea Limited Amid Uncertainty Following Phase 3 Trial Failure - TipRanks
Opthea Limited: Hold Rating Amid Phase 3 Trial Failure and Financial Uncertainty - TipRanks
Opthea’s COAST Phase 3 Trial Fails to Meet Primary Endpoint, Raising Financial Concerns - TipRanks
Opthea COAST trial misses primary endpoint, enters talks with DFA Investors - TipRanks
Promising Developments and Strong Financial Position Propel AbSci’s Growth Prospects - TipRanks
Opthea Limited Announces New Securities Quotation on ASX - TipRanks
Opthea Limited Reports Increased Losses Amid Clinical Advancements - TipRanks
Optimistic Buy Rating for Opthea Limited Driven by Promising Phase 3 Trials and Innovative AMD Treatment - TipRanks
Opthea reports mid-year financial results - Investing.com
Opthea Ltd completes key drug product campaign - Investing.com
Opthea Completes Key Phase 3 Trial Milestone in Wet AMD Treatment - TipRanks
Optimistic Outlook and Buy Rating for Opthea Limited Amid Promising Phase 3 Trials and Strong Financial Position - TipRanks
Opthea to Present at Oppenheimer Healthcare Conference - GlobeNewswire Inc.
OPTOpthea Limited American Depositary Shares Latest Stock News & Market Updates - StockTitan
Is Opthea Limited (OPT) One of the Best ASX Stocks to Buy According to Hedge Funds? - Insider Monkey
Opthea Unveils Promising Wet AMD Therapy at Investor Day - TipRanks
Why Opthea (OPT) Is Among the Best Australian Stocks to Buy Now? - Yahoo Finance
Jane Street Group LLC Invests $114,000 in Opthea Limited (NASDAQ:OPT) - Defense World
Opthea’s Innovative Approach to AMD Treatment with Sozinibercept - TipRanks
Opthea to Host Investor Days in New York and Australia - The Manila Times
Opthea Sets Key 2025 Investor Events to Showcase Breakthrough Wet AMD Treatment Sozinibercept - StockTitan
Opthea Limited Reports Earnings Results for the Half Year Ended December 31, 2024 - Marketscreener.com
EX-99.1 - SEC.gov
Opthea to Present Phase 3 Trial Update at J.P. Morgan Healthcare Conference - TipRanks
Opthea to Present at 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Race Oncology bolsters leadership - The Australian
Opthea's Wet AMD Program to be Featured at FLORetina 2024 - The Manila Times
Opthea’s Wet AMD Program to be Featured at FLORetina 2024 - Yahoo Finance
Opthea Highlights Innovative Wet AMD Therapy - TipRanks
Opthea to Participate in Citi 2024 Global Healthcare Conference - Yahoo Finance
Opthea Limited to Engage Investors at Healthcare Conference - TipRanks
Opthea CEO to Present at Citi Healthcare Conference, Spotlights Eye Disease Treatment - StockTitan
Opthea Limited Targets AMD Market with Sozinibercept - TipRanks
Opthea Appoints Kathy Connell to Board of Directors - The Manila Times
Opthea : Chairman’s Address to the 2024 Annual General Meeting Form 6 K - Marketscreener.com
Opthea Limited Announces Board Changes - Marketscreener.com
Opthea's Sozinibercept Shows Superior Results in Phase 2b Eye Disease Trial - StockTitan
Opthea's Wet AMD Program Featured at Ophthalmology Events - The Manila Times
Opthea (NASDAQ:OPT) Shares Up 1.7% – What’s Next? - Defense World
Opthea to Participate in November Investor Conferences - The Manila Times
Opthea : UPDATE Opthea to Participate in November Investor Conferences Form 6 K - Marketscreener.com
Opthea Limited Strengthens Leadership and Advances AMD Treatment - TipRanks
Opthea Limited Adr Stock (OPT) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.13%
0.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):